Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biotest AG
  6. News
  7. Summary
    BIO3   DE0005227235

BIOTEST AG

(BIO3)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Grifols, S.A. made an offer to acquire remaining 54.52% stake in Biotest Aktiengesellschaft for approximately €810 million.

09/17/2021 EDT

Grifols, S.A. (BME:GRF) made an offer to acquire remaining 54.52% stake in Biotest Aktiengesellschaft (XTRA:BIO3) for approximately €810 million on September 17, 2021. Under the terms, Grifols will acquire in cash Biotest’s ordinary and preferred shares for €43 and €37, respectively. In a related transaction, Grifols, S.A. (BME:GRF) entered into a share purchase agreement to acquire 45.48% stake in Biotest Aktiengesellschaft (XTRA:BIO3) from Tiancheng International Investment Limited for €1.1 billion. To fund the transaction, Grifols has received a bridge financing commitment for €2 billion unsecured bridge financing commitment provided by BofA Securities. Grifols plans to explore its financing options for unsecured debt. This acquisition will improve Grifol's plasma economics and revenue per liter bringing innovative plasma proteins to drive revenue growth and margin expansion. Tomás Dagá, Oscar Calsamiglia, Núria Martín, Eduard Arruga, Miguel Lorán, Laura De La Cruz, Ignasi Bruguer, Matthias Elser, Fabian Christoph, Sebastian Hack, Joachim Breithaupt, Andrew Saul and Matthew Edwards of Osborne Clarke and Proskauer Rose LLP acted as legal advisors and Nomura Securities International, Inc. and UBS Europe SE acted as financial advisors to Grifols.


© S&P Capital IQ 2021
All news about BIOTEST AG
10/11BIOTEST : COVID-19 Drug Cuts Risk Of Worsening, Death In Severely Ill Patients
MT
10/11BIOTEST AG : Biotest identifies a benefit with trimodulin in a relevant subgroup of hospit..
EQ
10/11PRESS RELEASE : Biotest AG: Biotest identifies a benefit with trimodulin in a relevant sub..
DJ
10/11Biotest Aktiengesellschaft Identifies A Benefit with Trimodulin in A Relevant Subgroup ..
CI
10/05GRIFOLS S A : Issues $2.3 Billion Senior Notes in Two-Tranche Deal to Fund Biotest Purchas..
MT
09/28GRIFOLS S A : Fitch Assigns BB- Rating to Grifols on 'Strong' Business Profile
MT
09/24GRIFOLS S A : Moody's Downgrades Grifols on Debt-Funded Acquisition of Biotest
MT
09/22GRIFOLS S A : S&P Maintains Grifols' Negative Outlook Amid $2.34 Billion Acquisition Of Bi..
MT
09/20BIOTEST AG : Release according to Article 40, Section 1 of the WpHG [the German Securities..
PU
09/20BIOTEST AG : Release according to Article 40, Section 1 of the WpHG [the German Securities..
DJ
More news
Financials
Sales 2021 509 M 593 M 593 M
Net income 2021 -21,1 M -24,6 M -24,6 M
Net Debt 2021 446 M 519 M 519 M
P/E ratio 2021 -82,0x
Yield 2021 0,07%
Capitalization 1 725 M 2 007 M 2 009 M
EV / Sales 2021 4,26x
EV / Sales 2022 3,99x
Nbr of Employees 1 963
Free-Float 55,1%
Chart BIOTEST AG
Duration : Period :
Biotest AG Technical Analysis Chart | BIO3 | DE0005227235 | MarketScreener
Technical analysis trends BIOTEST AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 43,80 €
Average target price 38,43 €
Spread / Average Target -12,3%
EPS Revisions
Managers and Directors
Michael Ramroth Chairman-Management Board & CFO
Rolf K. Hoffmann Chairman-Supervisory Board
Christian Polus Head-Information Technology
Georg Floß Chief Operations Officer
Oliver Hein Head-Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOTEST AG55.87%2 007
CSL LIMITED4.48%100 729
WUXI BIOLOGICS (CAYMAN) INC.10.21%61 841
SAMSUNG BIOLOGICS CO.,LTD.6.54%49 427
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.8.14%39 464